Ascentage Pharma Group International (NASDAQ:AAPG - Get Free Report) shares reached a new 52-week high during mid-day trading on Monday . The company traded as high as $29.72 and last traded at $29.71, with a volume of 35167 shares trading hands. The stock had previously closed at $28.38.
Analyst Upgrades and Downgrades
Separately, JPMorgan Chase & Co. started coverage on Ascentage Pharma Group International in a report on Thursday, March 27th. They set an "overweight" rating for the company.
View Our Latest Research Report on Ascentage Pharma Group International
Ascentage Pharma Group International Stock Up 4.0%
The stock has a 50-day simple moving average of $23.35.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Ascentage Pharma Group International stock. Monashee Investment Management LLC acquired a new position in shares of Ascentage Pharma Group International (NASDAQ:AAPG - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 159,942 shares of the company's stock, valued at approximately $3,511,000. Monashee Investment Management LLC owned approximately 0.18% of Ascentage Pharma Group International as of its most recent filing with the Securities and Exchange Commission.
Ascentage Pharma Group International Company Profile
(
Get Free Report)
Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Ascentage Pharma Group International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascentage Pharma Group International wasn't on the list.
While Ascentage Pharma Group International currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
